204 related articles for article (PubMed ID: 37142300)
1. Evaluation of Candidate Theranostics for
Abou DS; Longtine M; Fears A; Benabdallah N; Unnerstall R; Johnston H; Shim K; Hasson A; Zhang H; Ulmert D; Mangin F; Ozen S; Raibaut L; Brandès S; Meyer M; Chambron JC; Tatum DS; Magda D; Wahl RL; Thorek DLJ
J Nucl Med; 2023 Jul; 64(7):1062-1068. PubMed ID: 37142300
[No Abstract] [Full Text] [Related]
2. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
3. p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.
Deri MA; Ponnala S; Kozlowski P; Burton-Pye BP; Cicek HT; Hu C; Lewis JS; Francesconi LC
Bioconjug Chem; 2015 Dec; 26(12):2579-91. PubMed ID: 26550847
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
6. Quantitative 89Zr immuno-PET for in vivo scouting of 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice.
Verel I; Visser GW; Boellaard R; Boerman OC; van Eerd J; Snow GB; Lammertsma AA; van Dongen GA
J Nucl Med; 2003 Oct; 44(10):1663-70. PubMed ID: 14530484
[TBL] [Abstract][Full Text] [Related]
7. Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for
Raavé R; Sandker G; Adumeau P; Jacobsen CB; Mangin F; Meyer M; Moreau M; Bernhard C; Da Costa L; Dubois A; Goncalves V; Gustafsson M; Rijpkema M; Boerman O; Chambron JC; Heskamp S; Denat F
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1966-1977. PubMed ID: 31161258
[TBL] [Abstract][Full Text] [Related]
8. Impact of DOTA-Chelators on the Antitumor Activity of
Wojdowska W; Karczmarczyk U; Balog L; Sawicka A; Pöstényi Z; Kovács-Haász V; Polyák A; Laszuk E; Mikołajczak R; Garnuszek P
Cancer Biother Radiopharm; 2020 Oct; 35(8):558-562. PubMed ID: 32255676
[No Abstract] [Full Text] [Related]
9. Macrocyclic 1,2-Hydroxypyridinone-Based Chelators as Potential Ligands for Thorium-227 and Zirconium-89 Radiopharmaceuticals.
Woods JJ; Cosby AG; Wacker JN; Aguirre Quintana LM; Peterson A; Minasian SG; Abergel RJ
Inorg Chem; 2023 Dec; 62(50):20721-20732. PubMed ID: 37590371
[TBL] [Abstract][Full Text] [Related]
10. Light-Induced Radiosynthesis of
Klingler S; Fay R; Holland JP
J Nucl Med; 2020 Jul; 61(7):1072-1078. PubMed ID: 31924725
[TBL] [Abstract][Full Text] [Related]
11. Cure of Disseminated Human Lymphoma with [
Shim K; Longtine MS; Abou DS; Hoegger MJ; Laforest RS; Thorek DLJ; Wahl RL
J Nucl Med; 2023 Apr; 64(4):542-548. PubMed ID: 36357179
[TBL] [Abstract][Full Text] [Related]
12. Initial evaluation of (227)Th-p-benzyl-DOTA-rituximab for low-dose rate alpha-particle radioimmunotherapy.
Dahle J; Borrebaek J; Melhus KB; Bruland OS; Salberg G; Olsen DR; Larsen RH
Nucl Med Biol; 2006 Feb; 33(2):271-9. PubMed ID: 16546683
[TBL] [Abstract][Full Text] [Related]
13. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
14. Cure of Disseminated Human Lymphoma with [
Longtine MS; Shim K; Hoegger MJ; Benabdallah N; Abou DS; Thorek DLJ; Wahl RL
J Nucl Med; 2023 Jun; 64(6):924-931. PubMed ID: 37024304
[TBL] [Abstract][Full Text] [Related]
15. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging.
Perk LR; Vosjan MJ; Visser GW; Budde M; Jurek P; Kiefer GE; van Dongen GA
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):250-9. PubMed ID: 19763566
[TBL] [Abstract][Full Text] [Related]
16. Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89.
Zhai C; He S; Ye Y; Rangger C; Kaeopookum P; Summer D; Haas H; Kremser L; Lindner H; Foster J; Sosabowski J; Decristoforo C
Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30845658
[TBL] [Abstract][Full Text] [Related]
17. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry.
Salih AK; Raheem SJ; Garcia MD; Ahiahonu WK; Price EW
Inorg Chem; 2022 Dec; 61(51):20964-20976. PubMed ID: 36516446
[TBL] [Abstract][Full Text] [Related]
19. Cyclic versus Noncyclic Chelating Scaffold for
Summer D; Garousi J; Oroujeni M; Mitran B; Andersson KG; Vorobyeva A; Löfblom J; Orlova A; Tolmachev V; Decristoforo C
Mol Pharm; 2018 Jan; 15(1):175-185. PubMed ID: 29160082
[TBL] [Abstract][Full Text] [Related]
20. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
